Close Menu

NEW YORK – Biotechnology company Inotrem announced Tuesday it has entered a worldwide licensing agreement with Roche Diagnostics to commercialize a mechanism-based companion diagnostic test using soluble plasma protein sTREM-1.

The test will help identify which patients are more likely to respond to Inotrem's treatment, nangibotide, a TREM-1 inhibitor.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.